[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patientsDik J. Kwekkeboom, Eric P. Krenning, Willem H. Bakker et al.|European Journal of Nuclear Medicine and Molecular Imaging|2001Cited by 471
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumorsDik J. Kwekkeboom, Eric P. Krenning, Casper H.J. van Eijck et al.|Endocrine Related Cancer|2009Cited by 462
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceRoelf Valkema, Eric P. Krenning, Marion de Jong et al.|Seminars in Nuclear Medicine|2002Cited by 433
Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and BioavailabilityG Hennemann, Theo J. Visser, Roelof Docter et al.|Endocrine Reviews|2001Cited by 389
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsMarion de Jong, Eric P. Krenning, Roelf Valkema et al.|Seminars in Nuclear Medicine|2002Cited by 347